地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:17754422825
传真:18327026838
邮箱:sales@amyjet.com
<艾美捷科技代理Innovotech品牌全系列产品
Innovotech公司专注于抗菌及生物膜解决方案领域。公司在标准化和定制化研究领域拥有卓越业绩,始终致力于满足客户需求。Innovotech的合同研究服务涵盖全周期:从早期问题识别与"抗生物膜活性"制剂筛选,到符合监管机构要求的产品宣称验证研究,再到用于营销推广的上市后产品比对研究。公司常规开发客户定制化体外模型作为研究起点,支持多维度测试参数的全面检测。
Innovotech的研发体系主要建立在两大专利技术平台:MBEC检测法®(最小生物膜根除浓度测定)和BEST检测法™(生物膜表观生存力检测)。基于这些平台,公司已开发出系列独特检测方法,适用于医疗、牙科、农业及工业领域中各类溶液态抗菌剂与表面涂层抗菌剂的测试。公司还融合平台技术与生物膜、医疗器械及银化学等领域的专业知识,开发出自有抗生物膜产品线:InnovoSIL™系列在医疗器械应用领域展现显著潜力,AgreGuard™-1在农业应用测试中验证卓越效力。Innovotech已构建测试平台的生物膜问题涉及导管及植入式医疗器械、抗生素药物研发、伤口愈合管理、特种涂料与防护涂层、水系统抗菌解决方案、牙科治疗及供水管线抗菌方案、农作物细菌/真菌病害防治、食品加工硬表面消毒剂等领域。

▍Innovotech产品列表
| 品名 | 产品描述 | 货号 |
| MBEC Assay® Biofilm Inoculator with Trough Base & Cellulose Coated Pegs | The MBEC Assay® Biofilm Inoculator is a high throughput screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms. This MBEC Assay® Biofilm Inoculator consists of a plastic lid with 96 cellulose-coated pegs and a trough base. One of its recommended uses is with plant pathogens. | 10/cs:19193;25/cs:19191;100/cs:19192 |
| MBEC Assay® Biofilm Inoculator with 96 Well Base & Cellulose Coated Pegs | The MBEC Assay® Biofilm Inoculator is a high throughput screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms. This MBEC Assay® Biofilm Inoculator consists of a plastic lid with 96 cellulose-coated pegs and a well base. One of its recommended uses is with plant pathogens. | 10/cs:19173;25/cs:19171;100/cs:19172 |
| MBEC Assay® Biofilm Inoculator with Trough Base & Titanium Dioxide Coated Pegs | The MBEC Assay® Biofilm Inoculator is a high throughput screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms. The MBEC Assay® Biofilm Inoculator consists of a plastic lid with a Titanium Dioxide coated well base. | 10/cs:19163;25/cs:19161;100/cs:19162 |
| MBEC Assay® Biofilm Inoculator with 96 Well Base & Titanium Dioxide Coated Pegs | The MBEC Assay® Biofilm Inoculator is a high throughput screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms. The MBEC Assay® Biofilm Inoculator consists of a plastic lid with 96 Titanium Dioxide coated pegs and a well base. | 10/cs:19153;25/cs:19151;100/cs:19152 |
| MBEC Assay® Biofilm Inoculator with Trough Base & Hydroxyapatite Coated Pegs | The MBEC Assay® Biofilm Inoculator is a high throughput screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms. The MBEC Assay® Biofilm Inoculator consists of a plastic lid with a Hydroxyapatite coated a well base. | 10/cs:19143;25/cs:19141;100/cs:19142 |
| MBEC Assay® Biofilm Inoculator with 96 Well Base & Hydroxyapatite Coated Pegs | The MBEC Assay® Biofilm Inoculator is a high throughput screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms. The MBEC Assay® Biofilm Inoculator consists of a plastic lid with 96 Hydroxyapatite coated pegs and a well base. | 10/cs:19133;25/cs:19131;100/cs:19132 |
| MBEC Assay® Biofilm Inoculator with Trough Base | The MBEC Assay® Biofilm Inoculator is a high throughput screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms. The MBEC Assay® Biofilm Inoculator consists of a plastic lid with a trough base. | 10/cs:19123;25/cs:19121;100/cs:19122 |
| MBEC Assay® Biofilm Inoculator with 96 Well Base | The MBEC Assay® Biofilm Inoculator is a high throughput screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms. The MBEC Assay® Biofilm Inoculator consists of a plastic lid with 96 pegs well base. | 10/cs:19113;25/cs:19111;100/cs:19112 |
| InnovoSIL™-1 silver | The InnovoSIL™ family consists of novel antimicrobial silver complexes. InnovoSIL™-1 Antimicrobial Silver is ideally suited to coating onto or incorporating into medical devices, and is ready for testing. | - |

KENOSHA is the only truly specialized and independent provider of adhesive materials and related services to IVD and Medical Device manufacturers.
KENOSHA的主要产品包括:
(1)Lateral Flow
Backing Cards and Cover Tapes
Backing Cards Starter Kit
Conjugation Kits
(2)Medical Device
Medical Device Protective Packaging
Woundcare Adhesives
Filtration Media
Biosensor Films & Laminates
Medical Grade Adhesives
Microtiter Plate Sealing Tapes
IVD Trade
(3)Microfluidics
Microfluidic R2R
Paper-based Diagnostic Devices
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://eurogentec.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="KENOSHA"> KENOSHA
IBI Scientific是一家综合性的生物实验用品生产商,主要产品包括Belly Dancer Shaker、IBI electrophoresis、IBI Molecular Biology reagents和其他生物研究用品。
IBI Scientific is an ISO 9001:2015 Certified manufacturer of Life Science Research Products including laboratory equipment such as the Belly Dancer Shaker, IBI electrophoresis products, IBI Molecular Biology reagents, and many other high quality Life Science Research products.
IBI Scientific的主要产品包括:
Animal Holders
Beta Protection & Acrylic Lab Products
Electrophoresis
Lab Equipment
Microbiology Products
PCR Reagents
Purification Products
Reagents
Recombinant Proteins
UltraPure Water Products
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://eurogentec.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="IBI Scientific"> IBI Scientific
Eurotrol是一家国际化的质控品生产商,主要服务于诊断行业、PT/EQA(室间质评)项目、标准化单位、医院实验室等。其中,对于诊断和PT/EQA,Eurotrol能够提供定制化的产品和服务;对于标准化单位,Eurotrol为国际上具有声望的如ICSH、NIST提供标准品;Eurotrol提供还为医院实验室提供多种多样的即用型校准物、校准服务等。
Eurotrol具体详情,也可以咨询艾美捷科技丁香通商铺:
https://vicbio.biomart.cn/supply/c_281260.htm
CueSee® HbA1c
CueSee® Hyperbaric
CueSee® Hypoxic
CueSee® tHb
CueSee VeriSTAT® LVM
CueSee VeriSTAT® QC
GAS-ISE
GAS-ISE Metabolites
GAS-ISE Metabolites (with BUN)
GAS-ISE Protein
GlucoLin
GlucoTrol®-AQ
GlucoTrol®-NG
Hb 301 Control
Hct Control
Hematocrit Verification Fluids
HemoLin
HemoTrol®
HemoTrol® WB
HemoxiTrol
Homocysteine
ICSH HiCN Standard
Lipids
P
Plasma/Low Hb Control
Urine Chemistry
Vitamin A/E
Vitamin B1/B6
Eurotrol is a niche player in the world quality control market, offering a wide array of options. Our products have been tailored to meet the needs of the diagnostics industry (OEM), PT / EQA programs, standardization bodies, hospital laboratories and point of care sites.
Diagnostics industry and PT / EQA programs
Eurotrol customizes products for many medical device manufacturers as well as PT / EQA providers all over the world, providing a wide variety of products and services and offering unique packaging forms and processes to further enhance those products.
Standardization bodies
Over the years, Eurotrol has manufactured standards for such prestigious organizations as the International Council for Standardization in Hematology (ICSH) and the National Institute of Standards and Technology (NIST).
Hospital laboratories and point of care sites
Whether the need is for daily liquid quality controls or periodic calibration verification, Eurotrol's product lineup consists of ready-to-use products and services for laboratory and point of care instrumentation.
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
< " data-original="http://eurogentec.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Eurotrol"> Eurotrol
Kalen Biomedical为全世界范围内的心血管研究机构提供一流品质的脂蛋白(lipoprotein)。通过制定严格的生产流程和高标准的质控体系,Kalen Biomedical能够保证产品品质的持续稳定性。Kalen Biomedical的产品线包括天然的人类脂蛋白,氧化和乙酰化的低密度脂蛋白,此外还有脂蛋白探针、脂蛋白缺失血清和培养基。
Kalen Biomedical, LLC provides premium quality lipoproteins for the international cardiovascular research community. Kalen has developed stringent manufacturing procedures and Quality Control to ensure our products perform consistently.
Kalen’s lipoprotein product line includes native human lipoproteins and oxidized and acetylated Low Density Lipoproteins (LDL). Our lipoprotein probes offer the convenience of fluorescence or biotin labeled LDL. We supply lipoprotein depleted serum media supplement for specialized cell cultures (shipment to North America only).
Kalen Biomedical的主要产品包括:
Native Lipoproteins
Acetylated Lipoproteins
Oxidized Lipoproteins
Labeled Lipoproteins
Lipoprotein Depleted Sera
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
< " data-original="http://eurogentec.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Kalen Biomedical"> Kalen Biomedical
Premetek公司致力于为学术客户和工业客户提供化学试剂、纳米材料和催化剂,同时也提供多领域的研发服务。通过不断地与业内专业企业进行技术整合,Premetek不断更新产品,并为材料科学和催化领域提供了最多样化和可扩展的选择。
Our retail objectives are to offer the most expansive selection of premium products, provide easy and friendly service, offer the fastest delivery time possible, and ensure that every customer is satisfied with their purchase. Our inventory is determined by extensive market research, attendance at international tradeshows and conferences, customer feedback, and working closely with industry experts and vendors. Premetek is committed to continually improving our services and being the premier online market place for all your needs.
Premetek公司的主要产品包括:
Nanomaterials
Nanomaterial Suspension
Pt,Pd Catalysts -Hydrogenation
Pt,Pd Catalysts -Red/Oxidation
Pt Catalysts - Electrochemistry
Pt Alloy Catalysts - Electrochemistry
Pd Alloy Catalysts - Electrochemistry
Pd,Ru,Ir,Rh,Au Catalysts - Electrochemistry
Fe,Co,Ni,Cu,Ag Catalysts - Electrochemistry
Pt,Pd,Ru,Ir,Rh,Au-Organometallics
Pt, Pd, Rh Homogeneous Catalysts
Custom Products
Special catalysts in stock
| 品名 | 货号 | 规格 |
| Aluminum titanate, Al2TiO5, 40 g each | N10A1000 | 40g |
| Barium strontium titanium oxide, BaSrTi2O6, 40 g each | N10B2000 | 40g |
| Calcium titanate, CaTiO3, 40 g each | N10C1000 | 40g |
| Calcium zirconium titanium oxide, CaZrTi2O3, 40 g each | N10C2000 | 40g |
| Cadmium tungsten oxide, CdWO4, 40 g each | N10C3000 | 40g |
| Cerium aluminate, CeAlO3, 40 g each | N10C4000 | 40g |
| Copper aluminate, CuAl2O4, 40 g each | N10C5000 | 40g |
| Iron nickel oxide, FeNiO4, 40 g each | N10I1000 | 40g |
| Lanthanum chromite, LaCrO3, 40 g each | N10L1000 | 40g |
| Lanthanum manganite , LaMnO3, 40 g each | N10L3000 | 40g |
| Lanthanum substituted lithium titanate, (LaLi3)TiO3, 40 g each | N10L5000 | 40g |
| Lead zirconium substituted titanate, PbZr0.2Ti0.8O3, 40 g each | N10L6000 | 40g |
| Manganese titanate, MnTiO3, 40 g each | N10M1000 | 40g |
| Magnesium aluminate, MgAl2O4, 40 g each | N10M2000 | 40g |
| Nickel cobalt oxide, NiCoO2, 40 g each | N10N1000 | 40g |
| Strontium bismuth niobium oxide, SrBi2Nb2O9, 50 g each | N10S1000 | 40g |
| Strontium ferrite, SrFe12O19, 40 g each | N10S2000 | 40g |
| Yttrium aluminum oxide, Y3Al5O12, 40 g each | N10Y1000 | 40g |
| Yttrium iron oxide, Y3Fe5O12, 40 g each | N10Y2000 | 40g |
| Zinc iron oxide, ZnFe2O4, 40 g each | N10Z1000 | 40g |
| Zinc titanium oxide, ZnTiO3, 40 g each | N10Z2000 | 40g |
| Concentrated Suspension of Nanoscaled Titanium Dioxide (TiO2), 5 kg | N-1000 | 5kg |
| Concentrated Suspension of Nanoscaled Zinc Oxide (ZnO), 5 kg | N-2000 | 5kg |
| Concentrated Suspension of Nanoscaled Zinc Oxide (ZnO), 5 kg | N-2010 | 5kg |
| Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3000 | 5kg |
| Concentrated Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3010 | 5kg |
| Concentrated Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3020 | 5kg |
| Concentrated Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3130 | 5kg |
| Concentrated Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3220 | 5kg |
| Concentrated Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3230 | 5kg |
| 0.1% Pt on activated carbon powder, 10 g each | P10J1001 | 10g |
| 0.5% Pt on activated carbon powder, 10 g each | P10J1005 | 10g |
| 1.0% Pt on activated carbon powder, 10 g each | P10J1010 | 10g |
| 5.0% Pt on activated carbon powder, 10 g each | P10J1050 | 10g |
| 10% Pt on activated carbon powder, 10 g each | P10J1100 | 10g |
| 20% Pt on activated carbon powder, 10 g each | P10J1200 | 10g |
| 0.1% Pt on granular carbon, 10 g each | P10J2001 | 10g |
| 0.5% Pt on granular carbon, 10 g each | P10J2005 | 10g |
| 1.0% Pt on granular carbon, 10 g each | P10J2010 | 10g |
| 5.0% Pt on granular carbon, 10 g each | P10J2050 | 10g |
| 0.1% Pd on activated carbon powder, 10 g each | P30J1001 | 10g |
| 0.5% Pd on activated carbon powder, 10 g each | P30J1005 | 10g |
| 1.0% Pd on activated carbon powder, 10 g each | P30J1010 | 10g |
| 5.0% Pd on activated carbon powder, 10 g each | P30J1050 | 10g |
| 10% Pd on activated carbon powder, 10 g each | P30J1100 | 10g |
| 20% Pd on activated carbon powder, 10 g each | P30J1200 | 10g |
| 0.1% Pd on granular carbon, 10 g each | P30J2001 | 10g |
| 0.3% Pd on granular carbon, 10 g each | P30J2003 | 10g |
| 0.5% Pd on granular carbon, 10 g each | P30J2005 | 10g |
| 1.0% Pd on granular carbon, 10 g each | P30J2010 | 10g |
| 5.0% Pd on granular carbon, 10 g each | P30J2050 | 10g |
| 0.5% Pd on alumina spheres, 3 mm, SA= | P30L1005 | 10g |
| 1.0% Pd on alumina spheres, 3 mm, SA= | P30L1010 | 10g |
| 0.1% Pt on alumina powder, 10 g each | P10K1001 | 10g |
| 0.5% Pt on alumina powder, 10 g each | P10K1005 | 10g |
| 1.0% Pt on alumina powder, 10 g each | P10K1010 | 10g |
| 5.0% Pt on alumina powder, 10 g each | P10K1050 | 10g |
| 10% Pt on alumina powder, 10 g each | P10K1100 | 10g |
| 20% Pt on alumina powder, 10 g each | P10K1200 | 10g |
| 0.1% Pd on alumina powder, 10 g each | P30K1001 | 10g |
| 0.5% Pd on alumina powder, 10 g each | P30K1005 | 10g |
| 1.0% Pd on alumina powder, 10 g each | P30K1010 | 10g |
| 5.0% Pd on alumina powder, 10 g each | P30K1050 | 10g |
| 10% Pd on alumina powder, 10 g each | P30K1100 | 10g |
| 20% Pd on alumina powder, 10 g each | P30K1200 | 10g |
| 5% Pt on Vulcan XC-72 | P10A050 | 1g/5g |
| 10% Pt on Vulcan XC-72 | P10A100 | 1g/5g |
| 20% Pt on Vulcan XC-72 | P10A200 | 1g/5g |
| 30% Pt on Vulcan XC-72 | P10A300 | 1g/5g |
| 40% Pt on Vulcan XC-72 | P10A400 | 1g/5g |
| 50% Pt on Vulcan XC-72 | P10A500 | 1g/5g |
| 60% Pt on Vulcan XC-72 | P10A600 | 1g/5g |
| 80% Pt on Vulcan XC-72 | P10A800 | 1g/5g |
| Pt Black, High surface area: 40-50 m2/g, Low density: 0.6-0.9 g/ml | P10V010 | 1g/5g |
| 20% Pt on Durable Carbon | P10D200 | 1g/5g |
| 20% Pt on Vulcan XC-72R | P10B200 | 1g/5g |
| 40% Pt on Vulcan XC-72R | P10B400 | 1g/5g |
| 60% Pt on Vulcan XC-72R | P10B600 | 1g/5g |
| 40% Pt on high surface area Ketjenblack | P10E400 | 1g/5g |
| 50% Pt on high surface area Ketjenblack, | P10E500 | 1g/5g |
| 60% Pt on high surface area Ketjenblack | P10E600 | 1g/5g |
| 70% Pt on high surface area Ketjenblack | P10E700 | 1g/5g |
| 5% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A050 | 1g/5g |
| 10% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A100 | 1g/5g |
| 20% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A200 | 1g/5g |
| 30% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A300 | 1g/5g |
| 40% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A400 | 1g/5g |
| 50% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A500 | 1g/5g |
| 60% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72R | P12B600 | 1g/5g |
| 60% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A600 | 1g/5g |
| 80% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A800 | 1g/5g |
| Pt-Ru Black (1:1 atomic ratio) | P12V010 | 1g/5g |
| Pt-Ru Black (2.5:1 atomic ratio) | P12V250 | 1g/5g |
| Pt-Ru-Ir Black (1:1:1 atomic ratio) | P124V010 | 1g/5g |
| 50% Pt-Ru (1:1 atomic ratio) on Ketjenblack | P12E500 | 1g/5g |
| 60% Pt-Ru (1:1 atomic ratio) on Ketjenblack | P12E600 | 1g/5g |
| 75% Pt-Ru (1:1 atomic ratio) on Ketjenblack | P12E750 | 1g/5g |
| 20% Pt-Pd (1:3 atomic ratio) on Vulcan XC-72 | P13A203 | 1g/5g |
| 20% Pt-Pd (1:1 atomic ratio) on Vulcan XC-72 | P13A200 | 1g/5g |
| 20% Pt-Pd (3:1 atomic ratio) on Vulcan XC-72 | P13A230 | 1g/5g |
| 40% Pt-Pd (1:1 atomic ratio) on Vulcan XC-72 | P13A400 | 1g/5g |
| Pt-Pd Black (1:1 atomic ratio) | P13V010 | 1g/5g |
| Pt-Rh Black (1:1 atomic ratio) | P15V010 | 1g/5g |
| 20% Pt-Ir (1:3 atomic ratio) on Vulcan XC-72 | P14A203 | 1g/5g |
| 20% Pt-Ir (1:1 atomic ratio) on Vulcan XC-72 | P14A200 | 1g/5g |
| 20% Pt-Ir (3:1 atomic ratio) on Vulcan XC-72 | P14A230 | 1g/5g |
| 40% Pt-Ir (1:1 atomic ratio) on Vulcan XC-72 | P14A400 | 1g/5g |
| Pt-Ir Black (1:1 atomic ratio) | P14V010 | 1g/5g |
| 20% Pt-Cr (3:1 atomic ratio) on Vulcan XC-72 | P1AA230 | 1g/5g |
| 40% Pt-Cr (3:1 atomic ratio) on Vulcan XC-72 | P1AA430 | 1g/5g |
| 20% Pt-Fe (1:1 atomic ratio) on Vulcan XC-72 | P1BA200 | 1g/5g |
| 40% Pt-Fe (1:1 atomic ratio) on Vulcan XC-72 | P1BA400 | 1g/5g |
| 40% Pt-Fe (3:1 atomic ratio) on Vulcan XC-72 | P1BA430 | 1g/5g |
| 20% Pt-Co (1:1 atomic ratio) on Vulcan XC-72 | P1CA200 | 1g/5g |
| 20% Pt-Co (3:1 atomic ratio) on Vulcan XC-72 | P1CA230 | 1g/5g |
| 40% Pt-Co (1:1 atomic ratio) on Vulcan XC-72 | P1CA400 | 1g/5g |
| 40% Pt-Co (3:1 atomic ratio) on Vulcan XC-72 | P1CA430 | 1g/5g |
| 60% Pt-Co (3:1 atomic ratio) on Ketjenblack | P1CE630 | 1g/5g |
| 20% Pt-Ni (1:1 atomic ratio) on Vulcan XC-72 | P1DA200 | 1g/5g |
| 20% Pt-Ni (3:1 atomic ratio) on Vulcan XC-72 | P1DA230 | 1g/5g |
| 40% Pt-Ni (1:1 atomic ratio) on Vulcan XC-72 | P1DA400 | 1g/5g |
| 40% Pt-Ni (3:1 atomic ratio) on Vulcan XC-72 | P1DA430 | 1g/5g |
| 60% Pt-Ni (3:1 atomic ratio) on Ketjenblack | P1DE630 | 1g/5g |
| 20% Pt-Cu (1:1 atomic ratio) on Vulcan XC-72 | P1EA200 | 1g/5g |
| 20% Pt-Cu (3:1 atomic ratio) on Vulcan XC-72 | P1EA230 | 1g/5g |
| 20% Pt-Sn (3:1 atomic ratio) on Vulcan XC-72 | P1FA230 | 1g/5g |
| 40% Pt-Sn (3:1 atomic ratio) on Vulcan XC-72 | P1FA430 | 1g/5g |
| 20% Pd-Ir (1:3 atomic ratio) on Vulcan XC-72 | P34A203 | 1g/5g |
| 20% Pd-Ir (1:1 atomic ratio) on Vulcan XC-72 | P34A200 | 1g/5g |
| 20% Pd-Ir (3:1 atomic ratio) on Vulcan XC-72 | P34A230 | 1g/5g |
| 20% Pd-Rh (1:1 atomic ratio) on Vulcan XC-72 | P35A200 | 1g/5g |
| 20% Pd-Rh (3:1 atomic ratio) on Vulcan XC-72 | P35A230 | 1g/5g |
| 20% Pd-Ni (1:1 atomic ratio) on Vulcan XC-72 | P3DA200 | 1g/5g |
| 40% Pd-Au (1:1 atomic ratio) on Ketjenblack | P13E400 | 1g/5g |
| 5% Pd on Vulcan XC-72 | P30A050 | 1g/5g |
| 10% Pd on Vulcan XC-72 | P30A100 | 1g/5g |
| 20% Pd on Vulcan XC-72 | P30A200 | 1g/5g |
| 40% Pd on Vulcan XC-72 | P30A400 | 1g/5g |
| 40% Pd on Ketjenblack | P30E400 | 1g/5g |
| 60% Pd on Vulcan XC-72 | P30A600 | 1g/5g |
| 80% Pd on Vulcan XC-72 | P30A800 | 1g/5g |
| Pd Black, High surface area 40~48 m2/g | P30V010 | 1g/5g |
| 20% Ru on Vulcan XC-72 | P20A200 | 1g/5g |
| 40% Ru on Vulcan XC-72, | P20A400 | 1g/5g |
| Ru Black, High surface area 38~48 m2/g | P20V010 | 1g/5g |
| RuO2 powder, Surface area 18-25 m2/g | P20V020 | 1g/5g |
| 5% Ir on Vulcan XC-72 | P40A050 | 1g/5g |
| 10% Ir on Vulcan XC-72 | P40A100 | 1g/5g |
| 20% Ir on Vulcan XC-72 | P40A200 | 1g/5g |
| 40% Ir on Vulcan XC-72 | P40A400 | 1g/5g |
| Ir Black, High Surface area, 55~65 m2/g, | P40V010 | 1g/5g |
| IrOx powder, conductive, SA:10-20 m2/g | P40V020 | 1g/5g |
| Ru-Ir Black (1:1 atomic ratio) | P24V010 | 1g/5g |
| 20% Rh on Vulcan XC-72 | P50A200 | 1g/5g |
| Rh Black, High surface area 40~50 m2/g | P50V010 | 1g/5g |
| 20% Au on Vulcan XC-72 (Au particle size: 4-8 nm) | P60N200 | 1g/5g |
| 20% Au on Vulcan XC-72 (Au particle size: ~25 nm) | P60A200 | 1g/5g |
| 30% Au on Vulcan XC-72 (Au particle size: 8 nm) | P60N300 | 1g/5g |
| 40% Au on Vulcan XC-72 (Au particle size: ~35 nm) | P60A400 | 1g/5g |
| 40% Au on Ketjenblack (Au particle size: 4 nm) | P60E400 | 1g/5g |
| 60% Au on Vulcan XC-72 (Au particle size: ~45 nm) | P60A600 | 1g/5g |
| 5% Fe on Vulcan XC-72 | T10A050 | 1g/5g |
| 10% Fe on Vulcan XC-72 | T10A100 | 1g/5g |
| 20% Fe on Vulcan XC-72 | T10A200 | 1g/5g |
| 1% Co on Vulcan XC-72 | T20A010 | 1g/5g |
| 5% Co on Vulcan XC-72 | T20A050 | 1g/5g |
| 10% Co on Vulcan XC-72 | T20A100 | 1g/5g |
| 20% Co on Vulcan XC-72 | T20A200 | 1g/5g |
| 1% Ni on Vulcan XC-72 | T30A010 | 1g/5g |
| 5% Ni on Vulcan XC-72 | T30A050 | 1g/5g |
| 10% Ni on Vulcan XC-72 | T30A100 | 1g/5g |
| 20% Ni on Vulcan XC-72 | T30A200 | 1g/5g |
| 40% Ni on Vulcan XC-72 | T30A400 | 1g/5g |
| 1% Cu on Vulcan XC-72 | T40A010 | 1g/5g |
| 5% Cu on Vulcan XC-72 | T40A050 | 1g/5g |
| 10% Cu on Vulcan XC-72 | T40A100 | 1g/5g |
| 20% Cu on Vulcan XC-72 | T40A200 | 1g/5g |
| 40% Cu on Vulcan XC-72 | T40A400 | 1g/5g |
| 60% Cu on Vulcan XC-72 | T40A600 | 1g/5g |
| 20% Ag on Vulcan XC-72 | P70A200 | 1g/5g |
| 40% Ag on Vulcan XC-72 | P70A400 | 1g/5g |
| 60% Ag on Vulcan XC-72 | P70A600 | 1g/5g |
| 80% Ag on Vulcan XC-72 | P70A800 | 1g/5g |
| Platinum (II) acetylacetonate, 5 g each | P10H110 | 5g |
| (1,5-Cyclooctadiene)dimethylplatinum(II), 1 g each | P10H120 | 1g |
| Dichloro(1,5-cyclooctadiene)platinum(II), 5 g each | P10H130 | 5g |
| Diphenyl(1,5-cyclooctadiene)platinum(II), 5 g each | P10H140 | 5g |
| Trimethylbenzylammoniumhexachloroplatinate (IV), 1 g each | P10H150 | 1g |
| Palladium(II) acetylacetonate, 5 g each | P30H110 | 5g |
| Dichloro(1,5-cyclooctadiene)palladium(II), 5 g each | P30H120 | 5g |
| Hermann's Catalyst, 5 g each | P30H130 | 5g |
| 1,1'-Bis(di-tert-butylphosphino)ferrocene palladium dichloride, 1 g each | P30H140 | 1g |
| Bis(dibenzylideneacetone)palladium(0), 5 g each | P30H150 | 5g |
| Palladium(0) tetrakis(triphenylphosphine), 5 g each | P30H160 | 5g |
| Ruthenium(III) acetylacetonate, 5 g each | P20H110 | 5g |
| Dichloro(1,5-cyclooctadiene)ruthenium(II), polymer, 5 g each | P20H120 | 5g |
| Bis(cyclopentadienyl)ruthenium, 5 g each | P20H130 | 5g |
| Irridium(III) acetylacetonate, 5 g each | P40H110 | 5g |
| Chloro(1,5-cyclooctadiene)iridium(I) dimer, 5 g each | P40H120 | 5g |
| Rhodium(III) acetylacetonate, 5 g each | P50H110 | 5g |
| Chloro(1,5-cyclooctadiene)rhodium(I) dimer, 1 g each | P50H120 | 1g |
| Chloro(triphenylphosphine)gold(I), 5 g each | newitem3 | 5g |
| Bromo(triphenylphosphine)gold(I), 5 g each | P60H110 | 5g |
| Chloro(1,5-cyclooctadiene)rhodium(I) dimer, 98% 1 g | P50-002 | 1g |
| Chloro(1,5-cyclooctadiene)rhodium(I) dimer, 98% 1 g | P50-002 | 1g |
| Doyledirhodium catalyst-Rh2(5R-MPPIM)4, 1 g | P50-001 | 1g |
| Doyledirhodium catalyst-Rh2(5S-MPPIM)4, 1 g | P50-003 | 1g |
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

<| 产品名称 | 货号 | 化学式 | 分子量 | CAS# |
| 2,5-Anhydro-6-azido-6-deoxy-1,3-O-isopropylidene-D-glucitol | S20031 | C9H15N3O4 | 229,23 | N/A |
| 4-Azido-4-deoxy-1,6:2,3-dianhydro-β-D-mannopyranose | S97085 | C7H9N3O2 | 167,17 | N/A |
| Methyl-3,6-anhydro-7-azido-2,7-dideoxy-4,5-O-isopropylidene-D-alloheptonate | S10191 | C11H17H3O5 | 271,27 | N/A |
| 1,4-Anhydro-3-azido-2-O-benzoyl-3-deoxy-D-xylitol | S10192 | C12H13N3O4 | 263,25 | N/A |
| 1,4-Anhydro-2-azido-3-O-benzoyl-2-deoxy-D-arabitol | S10189 | C12H13N3O4 | 263,25 | N/A |
| 2-Azido-2-deoxy-1,4;3,6-dianhydro-D-glucitol | S03293 | C6H9N3O3 | 171,15 | N/A |
| 6-Azido-6-deoxy-1,2,3,4-tetra-O-acetyl-α,β-D-galactopyranose | S05174 | C14H19N3O9 | 373,32 | N/A |
| 6-Azido-6-deoxy-1,2,3,4-tetra-O-acetyl-α,β-L-galactopyranose | S02174 | C14H19N3O9 | 373,32 | N/A |
| DIBMA free acid | D-20054 | N/A | N/A | N/A |
| DIBMA monosodium salt | D-20055 | N/A | N/A | N/A |
| Glyco-DIBMA | D-20056 | N/A | N/A | N/A |
| n-Octyl α-D-glucopyranoside (aOG) > 99% highly purified | D97011 | C14H28O6 | 292,38 | 29781-80-4 |
| Methyl 6-O-(-n-heptylcarbamoyl)-α-D-glucopyranoside (HECAMEG) | D20034 | C15H29NO7 | 335,4 | 115457-83-5 |
| n-Hexyl β-D-glucopyranoside > 99% highly purified | D99014 | C12H24O6 | 264,4 | 59080-45-4 |
| n-Heptyl β-D-glucopyranoside (HeptG) > 99% highly purified | D07033 | C13H26O6 | 278,4 | 78617-12-6 |
| n-Octyl β-D-glucopyranoside (OG) > 99% highly purified | D97001 | C14H28O6 | 292,38 | 29836-26-8 |
| n-Octyl β-D-glucopyranoside (OG-C) > 99,5% for crystallography | D97001-C | C14H28O6 | 292,38 | 29836-26-8 |
| n-Nonyl β-D-glucopyranoside (NG) > 99% highly purified | D99011 | C15H30O6 | 306,40 | 69984-73-2 |
| n-Nonyl β-D-glucopyranoside (NG-C) > 99,5% for crystallography | D99011-C | C15H30O6 | 306,40 | 69984-73-2 |
| n-Decyl β-D-glucopyranoside (DG) > 99% highly purified | D99006 | C16H32O6 | 320,43 | 58846-77-8 |
| n-Undecyl β-D-glucopyranoside (UDG) > 99% highly purified | D11023 | C17H34O6 | 334,4 | 70005-86-6 |
| n-Dodecyl β-D-glucopyranoside (DDG) > 99% highly purified | D99007 | C18H36O6 | 348,5 | 59122-55-3 |
| 4-trans-(4-trans-Propylcyclohexyl)-cyclohexyl α-maltoside > 99% (t-PCCαM) | D99019-C | C27H47O11 | 547,67 | N/A |
| n-Dodecyl α-maltoside (αDDM) > 99% highly purified | D99020 | C24H46O11 | 510,63 | 116183-64-3 |
| n-Hexyl β-maltoside (HexM) > 99% highly purified | D20018 | C18H34O11 | 426,4 | 870287-95-9 |
| n-Heptyl β-maltoside (HeptM) > 99% highly purified | D14001 | C19H36O11 | 440,48 | N/A |
| n-Octyl β-maltoside (OM) > 99% highly purified | D20020 | C20H38O11 | 454,4 | 82494-08-4 |
| n-Nonyl β-maltoside (NM) > 99% highly purified | D20015 | C21H40O11 | 468,41 | 106402-05-5 |
| n-Nonyl β-maltoside (NM-C) > 99,5% for crystallography | D20015-C | C21H40O11 | 468,41 | 106402-05-5 |
| n-Decyl β-maltoside (DM) > 99% highly purified | D99003 | C22H42O11 | 482,6 | 82494-09-5 |
| n-Decyl β-maltoside (DM-C) > 99,5% for crystallography | D99003-C | C22H42O11 | 482,6 | 82494-09-5 |
| n-Undecyl β-maltoside (UDM) > 99% highly purified | D99012 | C23H44O11 | 496,6 | 253678-67-0 |
| n-Undecyl β-maltoside (UDM-C) > 99,5% for crystallography | D99012-C | C23H44O11 | 496,6 | 253678-67-0 |
| n-Dodecyl β-maltoside (DDM-C) > 99,5% for crystallography | D97002-C | C24H46O11 | 510,63 | 69227-93-6 |
| n-Tridecyl β-maltoside (TDM) > 99% | D20016 | C25H48O11 | 524,6 | 93911-12-7 |
| n-Tridecyl β-maltoside (TDM-C) > 99,5% for crystallography | D20016-C | C25H48O11 | 524,6 | 93911-12-7 |
| n-Tetradecyl β-maltoside (TeDM-C) > 99,5% for crystallography | D20028-C | C26H50O11 | 538,6 | 18449-82-6 |
| n-Pentadecyl β-maltoside (PDM-C) > 99,5% for crystallography | D20040-C | C27H52O11 | 552,35 | N/A |
| n-Hexadecyl β-maltoside (HeDM) > 99,5% | D20029-C | C28H54O11 | 566,72 | 98064-96-1 |
| n-Dodecyl β-maltoside (DDM) > 99% highly purified | D97002 | C24H46O11 | 510,63 | 69227-93-6 |
| Isopropyl 1-thio-β-D-galactopyranoside (IPTG) | S02122 | C9H18O5 | 238,30 | 367-93-1 |
| n-Heptyl 1-thio-β-D-glucopyranoside (HTG) > 99% highly purified | D99013 | C13H26O5S | 294,4 | 85618-20-8 |
| n-Octyl 1-thio-β-D-glucopyranoside (OTG) > 99% highly purified | D20014 | C14H28O5S | 308,44 | 85618-21-9 |
| n-Nonyl 1-thio-β-D-glucopyranoside (NTG-C) > 99,5% highly purified | D14038-C | C15H30O5S | 322,4 | 98854-15-0 |
| n-Decyl 1-thio-β-D-glucopyranoside (DTG) > 99% highly purified | D20021 | C16H32O5S | 336,4 | 98854-16-1 |
| n-Dodecyl 1-thio-β-maltoside (DDTM-C) > 99,5% highly purified | D20022-C | C24H46O10S | 526,6 | 148565-58-6 |
| n-Heptyl 1-thio-β-D-glucopyranoside (HTG-C) > 99,5% highly purified | D99013-C | C13H26O5S | 294,4 | 85618-20-8 |
| n-Octyl 1-thio-β-D-glucopyranoside (OTG-C) > 99,5% highly purified | D20014-C | C14H28O5S | 308,44 | 85618-21-9 |
| MEGA-8 (N-Octanoyl-N-methylglucamin) | D98004 | C15H31NO6 | 321,4 | 85316-98-9 |
| MEGA-9 (N-Nonanoyl-N-methylglucamin) | D99005 | C16H33NO6 | 335,4 | 85261-19-4 |
| MEGA-10 (N-Decanoyl-N-methylglucamin) | D99008 | C16H33NO6 | 335,4 | 85261-19-4 |
| 1-O-(n-Octyl)-tetraethyleneglycol (C8E4) | D20038 | C16H34O5 | 306,44 | 19327-39-0 |
| 1-O-(n-Decyl)-hexaethyleneglycol (C10E6) | D20041 | C22H46O7 | 422,60 | 5168-89-8 |
| 1-O-(n-Decyl)-nonaethyleneglycol (C10E9) | D20033 | C28H58O10 | 554,75 | 26183-52-81 |
| 1-O-(n-Dodecyl)-tetraethyleneglycol (C12E4) | D20035 | C20H42O5 | 362,54 | 5274-68-0 |
| 1-O-(n-Dodecyl)-octaethyleneglycol (C12E8) | D20039 | C28H58O9 | 538,75 | 3055-98-9 |
| 1-O-(n-Dodecyl)-nonaethyleneglycol (C12E9) | D20032 | C30H62O10 | 582,81 | 3055-99-0 |
| 1-O-(n-Dodecyl)-decaethyleneglycol (C12E10) | D20031 | C32H66O11 | 626,86 | 6540-99-4 |
| 1-O-(n-Tridecyl)-octaethyleneglycol (C13E8) | D20030 | C29H60O9 | 552,78 | 9043-30-5 |
| N,N-Dimethyl-n-dodecylamine-N-oxide (LDAO) | D71111 | C14H31NO | 229,4 | 1643-20-5 |
| Sucrose monolaurate (SUMOL) | S98001 | C24H44NO12 | 524,6 | 25339-99-5 |
| Monoolein (1-O-Oleoyl-rac-glycerol) | D20036 | C21H40O4 | 356,5 | 111-03-5 |
| 3-[(3-Cholamidopropyl)-dimethylammonio]-1-propane sulfonate | D99009 | C32H58N2O7S | 614,89 | 75621-03-3 |
| 3-[(3-Cholamidopropyl)-dimethylammonio]-2-hydroxy-1-propane sulfonate | D99010 | C32H58N2O8S | 630,87 | 82473-24-3 |
| n-Nonyl-phosphocholine (C9-PC) Purity > 99% | S10197 | C14H32NO4P | 309,38 | 253678-64-7 |
| n-Decyl-phosphocholine (C10-PC) Purity > 99% | S10195 | C15H34NO4P | 323,41 | 70504-28-8 |
| n-Undecyl-phosphocholine (C11-PC) Purity > 99% | S10196 | C16H36NO4P | 337,4 | 253678-65-8 |
| n-Dodecyl-phosphocholine (C12-PC) Purity > 99% | S10190 | C17H38NO4P | 351,46 | 29557-51-5 |
| n-Tridecyl-phosphocholine (C13-PC) Purity > 99% | S10198 | C18H40NO4P | 365,49 | 85775-42-4 |
| n-Tetradecyl-phosphocholine (C14-PC) Purity > 99% | S10194 | C19H42NO4P | 379,51 | 77733-28-9 |
| n-Pentadecyl-phosphocholine (C15-PC) Purity > 99% | S10199 | C20H44NO4P | 393,54 | 146801-07-2 |
| n-Hexadecyl-phosphocholine (C16-PC) Purity > 99% | S01241 | C21H46NO4P | 407,57 | 58066-85-6 |
| α-D-Galactopyranose-phosphate di-potassium salt dihydrate | P0001 | C6H11K2O9P. 2H2O | 372,36 | 19046-60-7 |
| α-D-Glucopyranose-phosphate di-potassium salt dihydrate | P0002 | C6H11K2O9P. 2H2O | 372,36 | 5996-14-5 |
| α-D-Mannopyranose-phosphate di-potassium salt dihydrate | P0003 | C6H11K2O9P. 2H2O | 372,36 | 71888-67-0 |
| N-Acetyl-D-galactosamine (2-Acetamido-2-deoxy-D-galactose, GalNAc) | S96001 | C8H15NO6 | 221,21 | 1811-31-0 |
| N-Acetyl-D-glucosamine (2-Acetamido-2-deoxy-D-glucose, GlcNAc) | S93002 | C8H15NO6 | 221,21 | 7512-17-6 |
| 2-Acetamido-2-deoxy-β-D-glucopyranosylamin | S98003 | C8H16N2O5 | 220,21 | 18615-50-4 |
| N-Acetyl-D-mannosamine x H2O (2-Acetamido-2-deoxy-D-mannose monohydrate, D-ManAc x H2O) | S94004 | C8H17NO7 | 239,23 | 7772-94-3 |
| 1,3,4,6-tetra-O-acetyl-β-D-GlcNAc (2-Acetamido-2-deoxy-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose) | S94005 | C16H23NO10 | 389.36 | 7772-79-4 |
| 3,4,6-tri-O-acetyl-β-D-GlcNAc azide (2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl azide) | S96006 | C14H20N4O8 | 372,34 | 6205-69-2 |
| 3,4,6-tri-O-acetyl-α-D-GlcNAc chlorid (2-Acetamido-2-deoxy-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl chlorid) | S97007 | C14H20CINO8 | 366,80 | 3068-34-6 |
| 1,3,4,6-tetra-O-acetyl-α-D-glucosamine x HCl (2-Amino-2-deoxy-1,3,4,6-tetra-O-acetyl-α-D-glucopyranose HCl) | S00116 | C14H22CINO9 | 383,79 | N/A |
| Allyl 2-acetamido-2-deoxy-α-D-glucopyranoside | S96008 | C11H19NO6 | 261,28 | 54400-75-8 |
| Allyl 2-acetamido-2-deoxy-β-D-glucopyranoside | S96009 | C11H19NO6 | 261,28 | 54400-77-0 |
| Allyl α-D-galactopyranoside | S96010 | C9H16O6 | 220,22 | 48149-72-0 |
| Allyl α-D-glucopyranoside | S98011 | C9H16O6 | 220,22 | 7464-56-4 |
| Allyl β-D-glucopyranoside | S98012 | C9H16O6 | 220,22 | 34384-797 |
| Allyl α-D-mannopyranoside | S11118 | C9H16O6 | 220,22 | 41308-76-3 |
| Allyl 2,3,4-tri-O-benzyl-α-D-glucopyranoside | S98013 | C30H34O6 | 490,60 | N/A |
| 1-Amino-1-deoxy-β-D-galactose (β-D-Galactopyranosylamine) | S99102 | C6H13NO5 | 179,17 | 50444-86-5 |
| 1,6-Anhydro-β-D-galactopyranose | S93014 | C6H10O5 | 162,14 | 644-76-8 |
| 1,6:3,4-Dianhydro-2-O-tosyl-β-D-galactopyranose | S97016 | C13H14O6s | 234,25 | 6167-32-4 |
| D-Arabinose | S93017 | C5H10O5 | 150,13 | 28697-53-2 |
| Arbutin (4-Hydroxyphenyl b-D-glucopyranoside, synthetic) | S96018 | C12H16O7 | 272,25 | 497-76-7 |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-α-D-galactopyranose | S96021 | C14H19N3O9 | 373,32 | N/A |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-α,β-D-galactopyranose | S97022 | C14H19N3O9 | 373,32 | N/A |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose | S96024 | C14H19N3O9 | 373,32 | N/A |
| 2-Azido-2-deoxy-1,2‘,3,3‘,4‘,6,6‘-hepta-O-acetyl-α,β-lactose 2-Azido-2-deoxy-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-1,3,6-tri-O-acetyl-α,β-D-glucopyranose | S96025 | C26H35N3O17 | 661,58 | N/A |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-α-D-mannopyranose | S97026 | C14H19N3O9 | 373,32 | N/A |
| Benzyl 4,6-O-benzylidene-α-D-GlcNAc | S97027 | C22H25NO6 | 399,45 | 13343-63-0 |
| Benzyl α-D-GlcNAc (Benzyl 2-acetamido-2-deoxy-α-D-glucopyranoside) | S97028 | C15H21NO6 | 311,34 | 13343-62-9 |
| Benzyl α-D-mannopyranoside | S97029 | C13H18O6 | 270,28 | 155548-45-5 |
| Cellobiose | S96030 | C12H22O11 | 342,30 | 528-50-7 |
| 6-Deoxy-1,2:3,4-di-O-isopropylidene-α-D-galactopyranose | S96032 | C12H20O5 | 244,29 | 4026-27-1 |
| 3,4-Di-O-acetyl-L-rhamnal (3,4-Di-O-acetyl-6-deoxy-L-glucal) | S94035 | C10H14O5 | 214.22 | 34819-86-8 |
| 1,4:3,6-Dianhydro-D-mannitol | S97037 | C6H10O4 | 146,15 | 641-74-7 |
| 1,2,3,4-Di-O-isopropylidene-α-D-galactopyranose | S95038 | C12H20O6 | 260.29 | 4064-06-6 |
| 1,2:5,6-Di-O-isopropylidene-α-D-glucofuranose | S00112 | C12H20O6 | 260,29 | 582-52-5 |
| 1,2:5,6-Di-O-isopropylidene-D-mannitol | S95039 | C12H22O6 | 262,31 | 1707-77-3 |
| 2,3:5,6-Di-O-isopropylidene-α-D-mannofuranose | S93040 | C12H20O6 | 260.29 | 14131-84-1 |
| 1,2:3,5-Di-O-isopropylidene-α-D-xylofuranose | S00110 | C11H18O5 | 230,26 | 20881-04-3 |
| D-Fucose (6-Deoxy-D-galactose) | S96042 | C6H12O6 | 164,16 [3615-37-0] | 3615-37-0 |
| L-Fucose (6-Deoxy-L-galactose) | S96043 | C6H12O6 | 164,16 | 2438-80-4 |
| D-Galactosamine x HCl | S95044 | C6H13NO5 x HCl | 215.64 | 1172-03-8 |
| D-Glucosamine x HCl | S93045 | C6H13NO5 x HCl | 215.64 | 66-84-2 |
| L-Glucose | S94046 | C6H12O6 | 180.16 | 921-60-8 |
| 2,3,3’,4,6,6’-Hexa-O-acetyl-lactal | S97036 | N/A | N/A | |
| 1,2-O-Isopropylidene-α-D-glucofuranose | S00113 | C9H16O6 | 220,22 | 18549-40-1 |
| Isopropyl-β-D-thiogalactoside IPTG (lactose based) | S02122-L | C9H18O5S | 238,31 | 367-93-1 |
| Isopropyl-β-D-thiogalactoside IPTG (on plant based) | S02122-P | C9H18O5S | 238,31 | 367-93-1 |
| 3,4-O-Isopropylidene-D-mannitol | S94048 | C9H18O6 | 222,22 | 369-84-4 |
| 1,2-O-Isopropylidene-α-D-xylofuranose | S00111 | C8H14O5 | 190,20 | 20031-21-4 |
| D-Lyxose | S96051 | C5H10O5 | 150,13 | 1114-34-7 |
| L-Lyxose | S96052 | C5H10O5 | 150,13 | 1949-78-6 |
| Maltose monohydrate | S98053 | C12H22O11H2O | 360,32 | 6363-53-7 |
| β-Maltose octaacetate | S98054 | C28H38O19 | 678,63 | 22352-19-8 |
| D-Mannose | S93057 | C6H12O6 | 180.16 | 3458-28-4 |
| L-Mannose | S94058 | C6H12O6 | 180.16 | 10030-80-5 |
| Methyl 4,6-O-benzylidene-β-D-galactopyranoside | S96060 | C14H18O6 | 282,30 | 6988-39-2 |
| Methyl 4,6-O-benzylidene-α-D-glucopyranoside | S97061 | C14H18O6 | 282,30 | 3162-96-7 |
| Methyl 4,6-O-benzylidene-β-D-glucopyranoside | S98062 | C14H18O6 | 282,30 | 6988-39-2 |
| Methyl 6-deoxy-α-L-mannopyranoside (Methyl a-L-rhamnopyranoside) | S96063 | C7H14O5 | 178,19 | 15814-59-2 |
| Methyl α-D-fucopyranoside | S96064 | C7H14O5 | 178,19 | 1128-40-1 |
| Methyl α-L-fucopyranoside | S96065 | C7H14O5 | 178,19 | 14687-15-1 |
| Methyl β-D-galactopyranoside | S96066 | C7H14O6 | 194,18 | 1824-94-8 |
| Methyl β-D-glucopyranoside hemihydrate | S96067 | C7H14O6 | 194,18 | 7000-27-3 |
| Methyl β-D-ribopyranoside | S97068 | C6H12O5 | 164,16 | 17289-61-1 |
| Methyl 2,3,5-tri-O-benzoyl-α-D-arabinofuranoside | S98069 | C27H24O8 | 476,49 | N/A |
| 1,2,3,4,6-Penta-O-acetyl-β-D-galactopyranose | S95072 | C16H22O11 | 390,35 | 4163-60-4 |
| 1,2,3,4,6-Penta-O-acetyl-α-D-mannopyranose | S99070 | C16H22O11 | 390,35 | 4163-65-9 |
| D-Raffinose pentahydrate | S96074 | C18H32O16 5H2O | 594,53 | 17629-30-0 |
| L-Rhamnose monohydrate | S94075 | C6H14O6 | 182.17 | 10030-85-0 |
| D-Ribose | S93076 | C5H10O5 | 150.13 | 50-69-1 |
| L-Ribose | S93077 | C5H10O5 | 150.13 | 24259-59-4 |
| D-Tagatose | S93079 | C6H12O6 | 180.16 | 87-81-0 |
| α-D-Talose | S93080 | C6H12O6 | 180.16 | 2595-98-4 |
| 2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl azide | S96081 | C14H19N3O9 | 373,32 | 13992-26-2 |
| 2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl bromide | S96082 | C14H19BrO9 | 411.21 | 3068-32-4 |
| 2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl azide | S96083 | C14H19N3O9 | 373,32 | 13992-25-1 |
| 2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl bromide | S94084 | C14H19BrO9 | 411.21 | 572-09-8 |
| 1,3,4,6-Tetra-O-acetyl-β-D-mannopyranose | S97086 | C14H20O10 | 348,31 | 18968-05-3 |
| 2,3,4,6-Tetra-O-acetyl-α-D-mannopyranose | S97087 | C14H20O10 | 348,31 | N/A |
| 1,2,3,5-Tetra-O-acetyl-β-D-ribofuranose | S94088 | C13H18O9 | 318.28 | 13035-61-5 |
| 2,3,4,6-Tetra-O-acetyl-1-thio-β-D-galactopyranose | S94089 | C14H20O9S | 364.37 | N/A |
| 2,3,4,6-Tetra-O-acetyl-1-thio-β-D-glucopyranose | S94090 | C14H20O9S | 364.37 | 19879-84-6 |
| 2,3,4,6-Tetra-O-benzyl-α-D-galactopyranose | S96091 | C34H3606 | 540.66 | 5308-25-7 |
| 2,3,4,6-Tetra-O-benzyl-α-D-glucopyranose | S93092 | C34H3606 | 540.66 | 4132-28-9 |
| 2,3,4,6-Tetra-O-benzyl-α-D-mannopyranose | S96093 | C34H3606 | 540.66 | 61330-61-8 |
| 1-Thio-β-D-galactose sodium salt | S96094 | C6H11NaO5S | 218,21 | 42891-22-5 |
| 1-Thio-β-D-glucose sodium salt dihydrate | S94095 | C6H11NaO5S x 2 H2O | 254.24 | 10593-29-0 |
| 3,4,6-Tri-O-acetyl-D-galactal | S94097 | C12H16O7 | 272.26 | 4098-06-0 |
| D-Turanose (α-D-Glcp(1-3)-D-fructose) | S93100 | C12H22O11 | 342.30 | 547-25-1 |
| D-Xylose | S93101 | C5H10O5 | 150.13 | 58-86-6 |
| 1,6-Anhydro-β-D-glucopyranose (Levoglucosan) | S93015 | C6H10O5 | 162,14 | 498-07-7 |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-α-D-glucopyranose | S96023 | C14H19N3O9 | 373,32 | N/A |
我们承诺:
(1)专业的服务:为您提供包括购买咨询、技术支持及实验方案制定在内的全方位服务;
(2)迅捷的货期:利用国际化的物流平台,大大缩短产品从厂家到最终用户的时间;
(3)过硬的品质:确保正品、质量和售后,多年客户积累,口碑保证。
公司简介:
艾美捷科技有限公司经营范围涵盖分子生物学试剂、免疫学试剂、细胞生物学试剂、蛋白质研究试剂、微生物学试剂、化学及生化试剂、材料学试剂、天然提取物、仪器设备等9大门类,累计约10万余种产品,充分满足不同客户的个性化需求;公司代理国外50余种一线品牌试剂,以“高性价比、迅捷的物流速度、专业的技术支持”,让客户充分享受全球化带来的便利;公司还增加了基因编辑、蛋白表达、细胞鉴定等定制项目,大大提升了为客户服务能力。“不忘初心,方得始终”,艾美捷科技将继续秉持“专心、专业、为您”的宗旨,以客户为根本,以诚信为基础,持续地为各界客户提供更加优质的产品和服务。
Glycon Biochemicals GmbH; Glycon Biochem; Glycon; S20031; S97085; S10191; S10192; S10189; S03293; S05174; S02174; D-20054; D-20055; D-20056; D97011; D20034; D99014; D07033; D97001; D97001-C; D99011; D99011-C; D99006; D11023; D99007; D99019-C; D99020; D20018; D14001; D20020; D20015; D20015-C; D99003; D99003-C; D99012; D99012-C; D97002-C; D20016; D20016-C; D20028-C; D20040-C; D20029-C; D97002; S02122; D99013; D20014; D14038-C; D20021; D20022-C; D99013-C; D20014-C; D98004; D99005; D99008; D20038; D20041; D20033; D20035; D20039; D20032; D20031; D20030; D71111; S98001; D20036; D99009; D99010; S10197; S10195; S10196; S10190; S10198; S10194; S10199; S01241; P0001; P0002; P0003; S96001; S93002; S98003; S94004; S94005; S96006; S97007; S00116; S96008; S96009; S96010; S98011; S98012; S11118; S98013; S99102; S93014; S97016; S93017; S96018; S96021; S97022; S96024; S96025; S97026; S97027; S97028; S97029; S96030; S96032; S94035; S97037; S95038; S00112; S95039; S93040; S00110; S96042; S96043; S95044; S93045; S94046; S97036; S00113; S02122-L; S02122-P; S94048; S00111; S96051; S96052; S98053; S98054; S93057; S94058; S96060; S97061; S98062; S96063; S96064; S96065; S96066; S96067; S97068; S98069; S95072; S99070; S96074; S94075; S93076; S93077; S93079; S93080; S96081; S96082; S96083; S94084; S97086; S97087; S94088; S94089; S94090; S96091; S93092; S96093; S96094; S94095; S94097; S93100; S93101; S93015; S96023; 10030-80-5; 10030-85-0; 10593-29-0; 106402-05-5; 106402-05-5; 111-03-5; 1114-34-7; 1128-40-1; 115457-83-5; 116183-64-3; 1172-03-8; 13035-61-5; 13343-62-9; 13343-63-0; 13992-25-1; 13992-26-2; 14131-84-1; 146801-07-2; 14687-15-1; 148565-58-6; 155548-45-5; 15814-59-2; 1643-20-5; 1707-77-3; 17289-61-1; 17629-30-0; 1811-31-0; 1824-94-8; 18449-82-6; 18549-40-1; 18615-50-4; 18968-05-3; 19046-60-7; 19327-39-0; 1949-78-6; 19879-84-6; 20031-21-4; 20881-04-3; 22352-19-8; 24259-59-4; 2438-80-4; 25339-99-5; 253678-64-7; 253678-65-8; 253678-67-0; 253678-67-0; 2595-98-4; 26183-52-81; 28697-53-2; 29557-51-5; 29781-80-4; 29836-26-8; 29836-26-8; 3055-98-9; 3055-99-0; 3068-32-4; 3068-34-6; 3162-96-7; 34384-797; 3458-28-4; 34819-86-8; 3615-37-0; 367-93-1; 367-93-1; 367-93-1; 369-84-4; 4026-27-1; 4064-06-6; 4098-06-0; 41308-76-3; 4132-28-9; 4163-60-4; 4163-65-9; 48149-72-0; 497-76-7; 498-07-7; 50444-86-5; 50-69-1; 5168-89-8; 5274-68-0; 528-50-7; 5308-25-7; 54400-75-8; 54400-77-0; 547-25-1; 572-09-8; 58066-85-6; 582-52-5; 58846-77-8; 58-86-6; 59080-45-4; 59122-55-3; 5996-14-5; 61330-61-8; 6167-32-4; 6205-69-2; 6363-53-7; 641-74-7; 644-76-8; 6540-99-4; 66-84-2; 69227-93-6; 69227-93-6; 6988-39-2; 6988-39-2; 69984-73-2; 69984-73-2; 7000-27-3; 70005-86-6; 70504-28-8; 71888-67-0; 7464-56-4; 7512-17-6; 75621-03-3; 7772-79-4; 7772-94-3; 77733-28-9; 78617-12-6; 82473-24-3; 82494-08-4; 82494-09-5; 82494-09-5; 85261-19-4; 85261-19-4; 85316-98-9; 85618-20-8; 85618-20-8; 85618-21-9; 85618-21-9; 85775-42-4; 870287-95-9; 87-81-0; 9043-30-5; 921-60-8; 93911-12-7; 93911-12-7; 98064-96-1; 98854-15-0; 98854-16-1

Rocky Mountain Diagnostics公司成立于2001年,主要产品涉及生物胺类、内分泌学、食品安全、研究分析/研究高敏感度、唾液试验、酶联免疫试剂盒等。
RMD was established in 2001 with a vision of marketing high quality in vitro diagnostics in the US. This vision, combined with the more than 40 years of experience of our partner organizations and exclusive dedication to immunodiagnostics, has made RMD together with its parent company the worldwide leaders in biogenic amine assays.
Rocky Mountain Diagnostics公司主要产品:
Biogenic Amines
Endocrinology
Food Safety - Featuring Histasure
Research Assays / Research High-Sensitive
Salivary Assays
Elisa Kit
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://eurogentec.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Rocky Mountain Diagnostics"> Rocky Mountain Diagnostics![]()
艾美捷科技代理Medix Biochemica品牌。
Medix Biochemica是重要的体外诊断原材料供应商,生产和供应高质量的抗体、抗原和其他关键的IVD原材料,涵盖免疫测定、临床化学和分子诊断等细分市场。Medix Biochemica拥有5000多种产品,可提供超过95%的最常见试剂,用于检测开发、生产和验证。Medix Biochemica提供高质量的单克隆抗体,也可以提供定制OEM服务,让抗体生产变得轻松。该工艺包括通过细胞系驯化、支原体检测、生产优化和验证进行评估和优化。
Medix Biochemica产品包括:
(1)抗体/抗原/酶:包含5000多种产品,涵盖300多种指标;
(2)MedixMDx:分子生物学应用原料;
(3)生物样本和生物材料。
< " data-original="http://eurogentec.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Medix Biochemica品牌"> 艾美捷科技代理Medix Biochemica品牌
艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://eurogentec.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172431432
传真:18327026838
邮箱:sales@amyjet.com
0.2802